Instil Bio (TIL) Receivables - Accured (2024 - 2026)

Instil Bio (TIL) posted quarterly Receivables - Accured of $8.0 million for Q1 2026, up 3.9% quarter-over-quarter from $7.7 million in Q4 2025.

Instil Bio (TIL) Receivables - Accured (2024 - 2026) Analysis & Trends

Instil Bio's Receivables - Accured history runs 3 years deep, the most recent figure standing at $8.0 million for Q1 2026.

In Q1 2026, Receivables - Accured changed N/A year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $8.0 million (changed N/A YoY), while the FY2025 annual figure was $7.7 million, up 79.07% from the prior year.
Receivables - Accured for Q1 2026 stood at $8.0 million, up from $7.7 million in the prior quarter.
The five-year high for Receivables - Accured was $8.0 million in Q1 2026, with the low at $4.3 million in Q4 2024.
The 3-year median for Receivables - Accured is $7.6 million (2025), against an average of $6.8 million.
Peak annual rise in Receivables - Accured reached 79.07% in 2025, while the deepest fall reached 79.07% in 2025.
Instil Bio's Receivables - Accured stood at $4.3 million in 2024, then surged by 79.07% to $7.7 million in 2025, then rose by 3.9% to $8.0 million in 2026.
Business Quant data shows TIL's Receivables - Accured at $8.0 million in Q1 2026, $7.7 million in Q4 2025, and $7.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.29 Bn	78.30 Bn	3.93 Bn	-
3	Argenx Se	65.17 Bn	59.98 Bn	1.37 Bn	-
4	Moderna	61.38 Bn	56.24 Bn	52.00 Mn	-
5	BeOne Medicines	42.18 Bn	37.09 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	30.99 Bn	27.68 Bn	992.69 Mn	-
7	BioNTech SE	28.45 Bn	10.05 Bn	668.28 Mn	-
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Instil Bio	50.93 Mn	50.93 Mn	-	8.30 Mn

Download Data